A Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Effects of CBN With and Without CBD on Sleep Quality

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

301 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-05-16

Study Completion Date

2022-12-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomized, double-blind, placebo-controlled, study to assess the safety and effects of CHI-560, CHI-563, CHI-564, \& CHI-565 versus placebo on sleep quality in healthy adult participants ages 18-55 years.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluating Efficacy and Safety of CBD TPM Capsules for Use in Insomnia

NCT05840822

Insomnia

RECRUITING PHASE3

The CANabidiol Use for RElief of Short Term Insomnia

NCT05253417

Sleep Disturbance Insomnia Insomnia Type; Sleep Disorder +3 more

COMPLETED PHASE2

Cannabinol Use in Patients With Insomnia Disorder

NCT05344170

Insomnia Disorder

COMPLETED PHASE1/PHASE2

Investigation of the Efficacy and Safety of CHI-921 in Insomnia.

NCT03984604

Insomnia

TERMINATED PHASE2

Clinical Study to Assess a Dietary Supplement on Sleep Health and Quality

NCT05368909

Sleep Quality Sleep Health

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Adults

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Intervention Type DIETARY_SUPPLEMENT

CBN and CBD in Gummy Format

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CBN and CBD

CBN and CBD in Gummy Format

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Person is between 18 and 55-years-old (inclusive).
2. Person has a BMI between 18 and 35 kg/m2 (inclusive).
3. Person is willing and able to provide informed consent.
4. Woman of childbearing potential must not be pregnant or currently breastfeeding.
5. Person agrees to abide by all study restrictions and comply with all study procedures.
6. Person rates past-week sleep quality on a 1 (very poor) to 5 (very good) rating scale as poor (2) or very poor (1).

Exclusion Criteria

1. Person has a known history of significant allergic condition, significant hypersensitivity to the IP, or allergic reaction to cannabis, cannabinoid medications, hemp products, or excipients of the IP.
2. Person has been exposed to any investigational drug or device \< 30 days prior to screening or plans to take an investigational drug in the near future (within 30 days).
3. Person has had a change in allowable medication, caffeine, tobacco, alcohol, supplement, or other drug use dose or regimen within 30 days of screening or has any plans to change dose or regimen during the course of the study.
4. Person has used cannabis, cannabinoid analogue (e.g., dronabinol, nabilone), and/or any CBD- or delta-9-tetrahydrocannabinol (THC)-containing product within 30 days of screening or during the study.
5. Person has history of use of any synthetic cannabinoid receptor agonist (e.g., spice, K2) within the past year.
6. Person is currently using products or medications that may interact with one or more of the ingredients in the IP, including the following drugs or supplements: warfarin, clobazam, valproic acid, phenobarbital, mechanistic target of rapamycin \[mTOR\] inhibitors, oral tacrolimus, St. John's wort, and Epidiolex.
7. Person has a positive screen (i.e., exceeds cut-point score) for any of the following sleep disorders on the Sleep Disorders Symptom Checklist-17 (SDS-CL-17): narcolepsy, obstructive sleep apnea, restless legs syndrome.
8. Person has a personal or family history (first-degree relative) of a psychotic disorder and/or schizophrenia.
9. Person endorses current suicidal intent as indexed via items 4 and 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS).
10. Person has an acute or progressive disease or disorder that is likely to interfere with the objectives of the study, or the ability to adhere to protocol requirements.
11. Person has a history of cardiovascular disease.
12. Woman of childbearing potential, unless she has not engaged in vaginal intercourse or she has used effective contraception when doing so (for example, oral contraception, double barrier, intra-uterine device) for at least 30 days prior to the study.
13. Woman of childbearing potential, unless willing to ensure that she or her partner use effective contraception (for example, oral contraception, double barrier, intra-uterine device) during the study and for 30 days thereafter (however, a male condom should not be used in conjunction with a female condom).
14. Man whose partner is of childbearing potential, unless willing to ensure that he or his partner use effective contraception (for example, oral contraception, double barrier, intra-uterine device) during the study and for 30 days thereafter (however, a male condom should not be used in conjunction with a female condom).
15. Person has history of diagnosis related to hepatic function and/or significantly impaired hepatic function (alanine aminotransferase \[ALT\] \>5 ⋅ upper limit of normal \[ULN\] or total bilirubin \[TBL\] \>2 ⋅ ULN) OR the ALT or aspartate aminotransferase (AST) \>3 ⋅ ULN and TBL \>2 ⋅ ULN (or international normalized ratio \[INR\] \>1.5).
16. Person demonstrates behavior indicating unreliability or inability to comply with the requirements of the protocol.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes